Cefilavancin - Theravance Biopharma
Alternative Names: Glycopeptide-cephalosporin heterodimer (TD-1792); Heterodimer antibacterial - Theravance Biopharma; TD-1792Latest Information Update: 02 Jul 2023
At a glance
- Originator GlaxoSmithKline; Theravance
- Developer R-Pharm; Theravance Biopharma
- Class Acetamides; Antibacterials; Azabicyclo compounds; Beta-lactams; Cephalosporins; Peptide antibiotics; Pyridines; Thiazoles
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Skin and soft tissue infections